$4.31
0.01 (+0.24%)
Trinity Biotech plc (ADR) (TRIB)
CAPS Rating:
The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

RSS Headlines
Fool UK
Recs
I picked this up totally at the wrong time (pretty much exactly 10 days too early), so I got hammered when the executive recently heavily discounted their stock to raise capital to finish paying off their 2006 purchase of the haemostasis business of French firm Biomerieux. As a result for the rest of you lucky investors out there, however, the stock is now sitting pretty at around 20% down from what I already considered a heck of a deal. I really wish I had the opportunity to buy into this company for the first time at this price and ride it from here.
Also, if you want more convincing, O'Caoimh, the executive chairman, just picked up 250,000 shares to supplement the 100,000 he bought on March 20. Not that insider trading necessarily means anything, but it's always nice to see executives having just bought over $1 milliion in their own company. http://www.forbes.com/markets/feeds/afx/2008/04/15/afx4890516.html
I see serious gains over the next year or two, maybe not all the way back up to to around 20, but at least to 10 (+ 300%). Here's hoping I'm right.